🟢 DFTX is trading 5.2% up today as investors cheer Phase 3 data and analyst upgrades

DFTX is trading 5.2% up at $38.59 as shares rebound from an equity offering pullback, with investors refocusing on positive Phase 3 clinical data for its depression treatment.

• The company reported pivotal Emerge Phase 3 results for DT120 in major depressive disorder, extending a significant rally for the stock.
• Shares are recovering from a pre-market dip caused by a ~$500 million equity offering as the market prioritizes clinical progress over dilution concerns.
• Analyst sentiment remains bullish, with Needham raising its price target to $50 and both JonesTrading and Canaccord reiterating Buy ratings.